• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Melanoma Trial Update Altering The Investment Case For Nanobiotix (ENXTPA:NANO)?

    Simply Wall St·11/06/2026 10:39:01
    Listen to the news
    • Nanobiotix released updated data from Phase 1 Study 1100 in anti-PD-1-resistant advanced primary cutaneous melanoma, reporting an Overall Response Rate of 41.7% in 24 heavily pre-treated patients and an acceptable safety profile for NBTXR3 in combination with radiotherapy and checkpoint inhibitors.
    • The one-time intratumoral NBTXR3 injection plus stereotactic radiotherapy showed responses in both injected and non-injected lesions. This hints at a potential systemic immune effect that could matter for how Nanobiotix positions NBTXR3 within existing melanoma treatment sequences.
    • We will look at how Nanobiotix's investment narrative is affected by these Phase 1 NBTXR3 melanoma data showing responses beyond injected lesions.
    Spot fresh oncology ideas by lining up Nanobiotix's NBTXR3 story against a hand-picked group of 124 healthcare AI stocks.

    Nanobiotix Investment Narrative Recap

    For Nanobiotix, the central belief is that NBTXR3 can move beyond a single niche and become part of routine radiotherapy-based treatment for a range of solid tumors. The updated melanoma Phase 1 data add another piece to that story, but the near-term equity case still depends most on execution in the Johnson & Johnson partnered head and neck and lung programs.

    The most important short-term catalyst remains progress or readouts from NANORAY 312 and the CONVERGE trial, rather than this early melanoma cohort. The largest risk is that key studies or partnership decisions do not support broad use of NBTXR3. That outcome would matter more for Nanobiotix than incremental Phase 1 melanoma signals.

    The melanoma update is the announcement that is most relevant here. It shows NBTXR3 used as a one-time intratumoral injection at the recommended Phase 2 dose together with stereotactic radiotherapy and checkpoint inhibitors in heavily pre-treated, anti–PD-1-resistant melanoma. The data include a 41.7% Overall Response Rate in 24 patients and responses in both injected and non-injected lesions.

    For you as a shareholder or prospective investor, this update still connects to the same central catalyst. Nanobiotix is aiming to show that NBTXR3 can be used across different tumor types and treatment settings so that Johnson & Johnson and other partners have reasons to continue committing resources. The downside risk, if larger trials disappoint or expansion decisions stall, remains the key operational factor to monitor.

    Analysts' current narrative for Nanobiotix points to forecast revenues of €88.2 million and projected earnings of €32.6 million by 2029, which implies revenue growth of 39.4% per year and an earnings swing of about €56.6 million from an earnings loss of €24.0 million today.

    Uncover why Nanobiotix's fair value indicates a 91% potential upside to its current price that may not last much longer.

    ENXTPA:NANO 1-Year Stock Price Chart
    ENXTPA:NANO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view puts funding risk at the center. Before this melanoma update, the most cautious analysts were modeling revenue of just €2.5 million and earnings of about €161.8 thousand by 2029 for Nanobiotix. That is far below consensus and reflects concern that key NBTXR3 programs might not support easier access to capital. You can treat this melanoma data and the upcoming Boston CEO presentation as potential turning points that could either soften that pessimistic story or reinforce it. It is worth reading several angles before forming your own view.

    Explore 3 other Nanobiotix fair value estimates, including one that suggests it could be worth just €40.00!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

    Looking For More Investment Ideas Beyond Nanobiotix?

    Once you have a view on Nanobiotix, it can help to set that opinion alongside other opportunities. The Simply Wall St Screener lets you quickly scan the market for companies that fit the kind of risk, income, or quality profile you are looking for.